Abstract

Sepsis management demands early diagnosis and timely treatment that includes source control, antimicrobial therapy, and resuscitation. Currently employed diagnostic tools are ill-equipped to rapidly diagnose sepsis and isolate the offending pathogen, which limits the ability to offer targeted and lowest-toxicity treatment. Cutting edge diagnostics and therapeutics in development may improve time to diagnosis and address two broad management principles: (1) source control by removing the molecular infectious stimulus of sepsis, and (2) attenuation of the pathological immune response allowing the body to heal. This review addresses novel diagnostics and therapeutics and their role in the management of sepsis.

Highlights

  • Sepsis begins with the activation of an innate immune response mediated by the detection of damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) by pattern-recognition receptors (PRRs) on host cells

  • Pathogen-associated molecular patterns (PAMPs) are unique motifs found on microbes that are recognized by PRRs, and allow the innate immune system to distinguish self from non-self, while Damage-associated molecular patterns (DAMPs) are a sign that there is damage to the host

  • Soluble triggering receptors expressed on myeloid cells are mainly distributed on the surface of polymorphonuclear cells and mature monocytes and are upregulated by bacterial lipopolysaccharides (LPS)

Read more

Summary

Introduction

Sepsis is a clinical syndrome resulting from a dysregulated inflammatory response to infection. Delayed identification and incorrect treatment lead to worse outcomes, increased costs, and higher mortality [2]. Managing sepsis in the contemporary era revolves around early diagnosis, administration of antimicrobials, hemodynamic support with fluids and vasopressors, and source control via procedural drainage and removal of the inciting pathogen. While these interventions have led to a decrease in hospital mortality, significant shortcomings in early recognition and treatment of the underlying cause of sepsis remain: the biomolecular triggering and subsequent inciting of an uncontrolled inflammatory response [4]. Overreliance on culture data delays identification of an infectious etiology and increases the possibility of inappropriate antimicrobial selection.

Materials and Methods
Novel Diagnostics in Sepsis
Summary of Biomarkers
PAMPS and DAMPS
Calprotectin
Soluble Urokinase-Type Plasminogen Activator Receptor
Presepsin
Novel Microcirculation-Related Biomarkers
Novel Biomarkers of Organ Dysfunction in Sepsis
Nanodiagnostics
Therapeutics
Pathogen-Associated Molecular Pattern Removal Devices
Bacteriophages
Intravenous Immunoglobulin
Targeted Monoclonal Antibodies
Liposomes
Alkaline Phosphatase
Antimicrobial Peptides
Nanoparticles
Angiotensin 2
Selepressin
Mesenchymal Stem Cells
Extracellular Vesicles
Toll-Like Receptor Ligand Binders
Interleukin Agonists and Antagonists
Adrenomedullin
Eculizumab
4.2.10. Interferon Gamma
4.2.11. Triggering Receptor Expressed on Myeloid Cells-1 and Nangibotide
4.2.12. Immune Checkpoint Modulators
Findings
4.2.13. Granulocyte-Macrophage Colony-Stimulating Factor
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.